Frequently Asked Questions (FAQs) about SUPARTZ | Ordering | Insurance Coverage & Reimbursement| NHRIC: 08363-7761-01 | National HCPCS Code: J7321

Frequently Asked Questions (FAQs)

1. Who is a candidate for SUPARTZ?

Patients with osteoarthritis (OA) of the knee who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. Use caution when administering SUPARTZ to patients who are allergic to avian proteins, feathers, and egg products. (1) The safety and effectiveness of SUPARTZ have not been established in pregnant women, lactating women, or children.

More info

2. How is SUPARTZ administered?

SUPARTZ is administered by intra-articular injections once a week (1 week apart) for a total of 5 injections. Some patients may experience benefit with 3 injections given at weekly intervals. (2) This means that you decide for yourself when a patient's needs have been met. Injection of subcutaneous lidocaine or similar local anesthetic may be recommended prior to injection of SUPARTZ. There is 25 mg/2.5 mL active ingredient per syringe.

More info

3. How does SUPARTZ work?

The mechanical, cellular, and biochemical processes associated with knee OA may cause inflammation, stiffness and reduced mobility, synovial changes, and progressive degeneration. SUPARTZ treats knee OA by supplementing the natural synovial fluid in the knee. Oral analgesics and NSAIDs affect all parts of the body while SUPARTZ specifically targets osteoarthritis in the knee.

More info

4. What are the key clinical benefits of SUPARTZ?

In clinical trials, SUPARTZ has been shown to relieve OA knee pain:

  • SUPARTZ significantly relieved OA pain, a benefit that lasted at least 18 weeks, in a multicenter, prospective, randomized, double-blind, placebo-controlled study of 240 patients with knee OA (3)
  • In an integrated analysis of 5 clinical studies, SUPARTZ yielded a significantly greater reduction in pain compared with saline (4)

In addition, SUPARTZ offers a safety profile similar to saline

  • No difference in adverse events following SUPARTZ vs. saline placebo (1,4)
  • Discontinuation rates due to adverse events were 1.8% for SUPARTZ and 3.2% for placebo (4)
  • No reports of pseudoseptic reactions in the scientific literature (5)*

*Does not include current prescribing experience.

More info

5. How do I order SUPARTZ?

To order SUPARTZ, or for further information, contact Bioventus by calling toll-free: 1-800-396-4325

Catalog Number: 7156-5555
1-syringe package

Description: Plastic syringe with Luer-Lok needle attachment
Other Information: Shelf life of 42 months. Each syringe contains 1% sodium hyaluronate (25 mg).

More info

6. Where can I find reimbursement information for prescribing SUPARTZ?

SUPARTZ is covered by Medicare and most private insurance companies if medical necessity and other coverage requirements are satisfied. If you have questions about local coverage of SUPARTZ or insurance verifications, please call:

Reimbursement Hotline: 855-870-0920

Reimbursement Verification Fax Line: 855-389-2239

Hotline Hours:
     8:00 am - 8:00 pm Eastern
     7:00 am - 7:00 pm Central
     5:00 am - 5:00 pm Pacific

More info

7. What other resources are available?

These organizations offer resources that may be helpful to you and your patients.

  1. SUPARTZ (package insert). Durham, NC: Bioventus LLC; 2012.
  2. Karlsson J, Sjögren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology (Oxford). 2002;41(11):1240-1248.
  3. Day R, Brooks P, Conaghan PG, Peterson M. A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the knee. J Rheumatol. 2004;31(4):775-782.
  4. Strand V, Conaghan PG, Lohmander LS, et al. An integrated analysis of five double-blind, randomized controlled trials evaluating the safety and efficacy of a hyaluronan product for intra-articular injection in osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14:859-866.
  5. SUPARTZ file of prospective clinical studies. Regulatory file 29000.142.